en
svPress releases
Regulatory press release 2024-02-12
FDA Accepts Xspray Pharma’s NDA-resubmission for Dasynoc® – PDUFA Date set to 31 July
Regulatory press release 2024-02-07
Xspray Pharma appoints Michael af Winklerfelt as acting CFO
Regulatory press release 2023-12-29
New number of shares and votes in Xspray Pharma
Regulatory press release 2023-12-01
Xspray Pharma raises SEK 92.3 million through warrants TO5
Regulatory press release 2023-11-09
Xspray Pharma’s large shareholders and key individuals declare their intent to exercise TO5 warrants in November
Regulatory press release 2023-11-08
Interim Report Third Quarter 2023
Regulatory press release 2023-10-24
Xspray Pharma’s Nomination Committee for the Annual General Meeting 2024
Regulatory press release 2023-09-11
Xspray Pharma and Bristol Myers Squibb Reach Settlement on Dasynoc™ Patent Litigation, Paving Way for Early Market Launch
Regulatory press release 2023-08-02
Interim Report Second Quarter 2023
Regulatory press release 2023-07-31